Printer Friendly

POSSIS MEDICAL RECEIVES FDA APPROVAL FOR IDE APPLICATION

 POSSIS MEDICAL RECEIVES FDA APPROVAL FOR IDE APPLICATION
 MINNEAPOLIS, July 20 /PRNewswire/ -- Possis Corporation


(NASDAQ: POSS) announced today that Possis Medical, Inc. (PMI), its wholly owned subsidiary, has received U.S. Food and Drug Administration (FDA) approval of its Perma-Seal(TM) Dialysis Graft Investigational Device Exemption (IDE) application. PMI will now proceed with the process of preparing for human clinical trials.
 Perma-Seal is a unique, isodiametric (straight) dialysis graft using PMI's proprietary material, a composite of porous, silicone rubber and polyester thread. The graft has excellent anti-kink and anti-crush properties. Compared to conventional synthetic dialysis grafts, Perma- Seal offers self-sealing properties that enhance the possibility for early graft cannulation and reduce the chances for excessive bleeding and tissue ingrowth. PMI believes Perma-Seal offers important advantages for the estimated 40,000 patients per year worldwide who require graft implantation for kidney dialysis.
 Taken together with PMI's Perma-Flow(R) Coronary Graft, which is currently awaiting its initial human implant, the Perma-Seal approval further establishes PMI as an emerging provider of synthetic peripheral grafts and a pioneer in providing synthetic coronary grafts.
 PMI recently leased an additional 5,000 square feet of contiguous space at its now 30,000 square foot facility in Plymouth, Minn., to support increasing production requirements for clinical trials and anticipated international sales of PMI's Perma-Flow Coronary Graft, Perma-Seal Dialysis Graft and AngioJet(TM) thrombectomy system. PMI currently employs 95 employees, up from 69 one year ago.
 -0- 7/20/92
 /CONTACT: Robert G. Dutcher of Possis Medical, 612-550-1010/
 (POSS) CO: Possis Corporation; Possis Medical, Inc. ST: Minnesota IN: MTC SU:


KH -- MN001 -- 0609 07/20/92 09:44 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1992
Words:271
Previous Article:ATLANTA GAS LIGHT COMPANY ISSUES CORRECTING STATEMENT
Next Article:TECHTEAM ANNOUNCES RECORD INCREASE IN REVENUES AND EARNINGS FOR THE SECOND QUARTER AND THE FIRST SIX MONTHS OF 1992
Topics:


Related Articles
POSSIS RECEIVES IDE APPROVAL FROM FDA
CARDIOPULMONICS REPORTS PMA SUBMISSION
CRYOLIFE, INC. SUBMITS PREMARKET APPROVAL (PMA) APPLICATION TO FDA ON CRYOPRESERVED HEART VALVES
CRYOLIFE, INC. GRANTED FDA APPROVAL TO EXPAND IMPLANT PROGRAM FOR HUMAN ALLOGRAFT HEART VALVES
POSSIS MEDICAL, INC. APPLIES TO FDA FOR COMMENCEMENT OF ANGIOJET(TM) CORONARY THROMBECTOMY STUDY
POSSIS MEDICAL FILES 510(k) AND IDE APPLICATIONS AND RECEIVES SECOND U.S. PATENT FOR ANGIOJET RAPID THROMBECTOMY SYSTEM
POSSIS MEDICAL, INC. RECEIVES FDA APPROVAL FOR PHASE 2 STUDY OF ANGIOJET CORONARY THROMBECTOMY SYSTEM
Possis Medical Inc. Moves Toward U.S. Marketing Clearance For AngioJet
Possis Medical Obtains Humanitarian Designation for Its Perma-Flow Graft
Possis Medical, Inc. Seeks FDA Approval to Begin Stroke Clinical Trial with the AngioJet System

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters